BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 10769696)

  • 1. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody MOv18.
    Andersson H; Lindegren S; Back T; Jacobsson L; Leser G; Horvath G
    Anticancer Res; 2000; 20(1A):459-62. PubMed ID: 10769696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer.
    Andersson H; Palm S; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
    Anticancer Res; 2001; 21(1A):409-12. PubMed ID: 11299770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study.
    Andersson H; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
    Acta Oncol; 2000; 39(6):741-5. PubMed ID: 11130014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
    Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
    Andersson H; Elgqvist J; Horvath G; Hultborn R; Jacobsson L; Jensen H; Karlsson B; Lindegren S; Palm S
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3914S-21S. PubMed ID: 14506189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
    Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histopathological study of subcutaneous heterograft of human gastric cancer in nude mice treated with 211At labelled monoclonal antibody].
    Luo DY
    Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):23-5. PubMed ID: 8334936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.
    Gustafsson AM; Bäck T; Elgqvist J; Jacobsson L; Hultborn R; Albertsson P; Morgenstern A; Bruchertseifer F; Jensen H; Lindegren S
    Nucl Med Biol; 2012 Jan; 39(1):15-22. PubMed ID: 21958859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
    Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
    Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
    J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.
    Beck R; Seidl C; Pfost B; Morgenstern A; Bruchertseifer F; Baum H; Schwaiger M; Senekowitsch-Schmidtke R
    Cancer Sci; 2007 Aug; 98(8):1215-22. PubMed ID: 17561973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
    J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
    Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.
    Frost SH; Bäck T; Chouin N; Hultborn R; Jacobsson L; Elgqvist J; Jensen H; Albertsson P; Lindegren S
    Cancer Biother Radiopharm; 2013 Mar; 28(2):108-14. PubMed ID: 23230896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
    Zalutsky MR; McLendon RE; Garg PK; Archer GE; Schuster JM; Bigner DD
    Cancer Res; 1994 Sep; 54(17):4719-25. PubMed ID: 8062270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.